Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Nov;30(5):719–724. doi: 10.1128/aac.30.5.719

Xylotubercidin against herpes simplex virus type 2 in mice.

E De Clercq, M J Robins
PMCID: PMC176520  PMID: 3800347

Abstract

Of a series of newly synthesized derivatives of the pyrrolo[2,3-d]pyrimidine nucleosides tubercidin, toyocamycin, and sangivamycin, the xylosyl analog of tubercidin, xylotubercidin, exhibited the greatest potency and selectivity against herpes simplex virus type 2 (HSV-2) in vitro. At dosage regimens that were not toxic for the host, xylotubercidin proved efficacious in various HSV-2 animal model infections. When applied topically at 0.25, 0.5, or 1% in dimethyl sulfoxide or when administered systemically (intraperitoneally) at 12.5 or 25 mg/kg per day, xylotubercidin suppressed the development of herpetic skin lesions and the paralysis and mortality associated therewith in hairless mice inoculated intracutaneously with HSV-2. In this model, acyclovir was effective only if administered topically at 5 or 10% in dimethyl sulfoxide. When administered intraperitoneally over a dosage range of 10 to 50 mg/kg per day, xylotubercidin achieved a significant reduction in the mortality rate of mice infected intraperitoneally with HSV-2. Under the same conditions, acyclovir did not offer any protection even when administered at doses up to 250 mg/kg per day. Xylotubercidin thus appears to have considerable potential for both topical and systemic treatment of HSV-2 infections.

Full text

PDF
724

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alenius S., Nordlinder H. Effect of trisodium phosphonoformate in genital infection of female guinea pigs with herpes simplex virus type 2. Arch Virol. 1979;60(3-4):197–206. doi: 10.1007/BF01317491. [DOI] [PubMed] [Google Scholar]
  2. Aswell J. F., Allen G. P., Jamieson A. T., Campbell D. E., Gentry G. A. Antiviral activity of arabinosylthymine in herpesviral replication: mechanism of action in vivo and in vitro. Antimicrob Agents Chemother. 1977 Aug;12(2):243–254. doi: 10.1128/aac.12.2.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bergstrom D. E., Brattesani A. J., Ogawa M. K., Reddy P. A., Schweickert M. J., Balzarini J., De Clercq E. Antiviral activity of C-5 substituted tubercidin analogues. J Med Chem. 1984 Mar;27(3):285–292. doi: 10.1021/jm00369a010. [DOI] [PubMed] [Google Scholar]
  4. Bryson Y. J., Dillon M., Lovett M., Acuna G., Taylor S., Cherry J. D., Johnson B. L., Wiesmeier E., Growdon W., Creagh-Kirk T. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983 Apr 21;308(16):916–921. doi: 10.1056/NEJM198304213081602. [DOI] [PubMed] [Google Scholar]
  5. Burns W. H., Saral R., Santos G. W., Laskin O. L., Lietman P. S., McLaren C., Barry D. W. Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet. 1982 Feb 20;1(8269):421–423. doi: 10.1016/s0140-6736(82)91620-8. [DOI] [PubMed] [Google Scholar]
  6. Cass C. E., Selner M., Tan T. H., Muhs W. H., Robins M. J. Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin. Cancer Treat Rep. 1982 Feb;66(2):317–326. [PubMed] [Google Scholar]
  7. Corey L., Fife K. H., Benedetti J. K., Winter C. A., Fahnlander A., Connor J. D., Hintz M. A., Holmes K. K. Intravenous acyclovir for the treatment of primary genital herpes. Ann Intern Med. 1983 Jun;98(6):914–921. doi: 10.7326/0003-4819-98-6-914. [DOI] [PubMed] [Google Scholar]
  8. Corey L., Nahmias A. J., Guinan M. E., Benedetti J. K., Critchlow C. W., Holmes K. K. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982 Jun 3;306(22):1313–1319. doi: 10.1056/NEJM198206033062201. [DOI] [PubMed] [Google Scholar]
  9. Crumpacker C. S., Schnipper L. E., Marlowe S. I., Kowalsky P. N., Hershey B. J., Levin M. J. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med. 1982 Feb 11;306(6):343–346. doi: 10.1056/NEJM198202113060606. [DOI] [PubMed] [Google Scholar]
  10. Davis W. B., Oakes J. E., Taylor J. A. Effect of treatment with 5-ethyl-2'-deoxyuridine on herpes simplex virus encephalitis in normal and immunosuppressed mice. Antimicrob Agents Chemother. 1978 Nov;14(5):743–748. doi: 10.1128/aac.14.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. De Cercq E., Luczak M. Fluoroimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesis. Life Sci. 1975 Jul 15;17(2):187–194. doi: 10.1016/0024-3205(75)90502-0. [DOI] [PubMed] [Google Scholar]
  12. De Clercq E. Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother. 1985 Jul;28(1):84–89. doi: 10.1128/aac.28.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. De Clercq E., Balzarini J., Torrence P. F., Mertes M. P., Schmidt C. L., Shugar D., Barr P. J., Jones A. S., Verhelst G., Walker R. T. Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2'-deoxyuridines on mouse leukemia L1210 cell growth. Mol Pharmacol. 1981 Mar;19(2):321–330. [PubMed] [Google Scholar]
  14. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  15. Douglas J. M., Critchlow C., Benedetti J., Mertz G. J., Connor J. D., Hintz M. A., Fahnlander A., Remington M., Winter C., Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984 Jun 14;310(24):1551–1556. doi: 10.1056/NEJM198406143102402. [DOI] [PubMed] [Google Scholar]
  16. Fraser-Smith E. B., Eppstein D. A., Marsh Y. V., Matthews T. R. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother. 1984 Dec;26(6):937–938. doi: 10.1128/aac.26.6.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fraser-Smith E. B., Eppstein D. A., Marsh Y. V., Matthews T. R. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother. 1984 May;25(5):563–565. doi: 10.1128/aac.25.5.563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fraser-Smith E. B., Eppstein D. A., Marsh Y. V., Matthews T. R. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with gamma interferon against herpes simplex virus type 2 in mice. Antiviral Res. 1985 Jun;5(3):137–144. doi: 10.1016/0166-3542(85)90046-4. [DOI] [PubMed] [Google Scholar]
  19. Fraser-Smith E. B., Smee D. F., Matthews T. R. Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother. 1983 Dec;24(6):883–887. doi: 10.1128/aac.24.6.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kern E. R., Glasgow L. A., Overall J. C., Jr, Reno J. M., Boezi J. A. Treatment of experimental herpesvirus infections with phosphonoformate and some comparisons with phosphonoacetate. Antimicrob Agents Chemother. 1978 Dec;14(6):817–823. doi: 10.1128/aac.14.6.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kern E. R., Richards J. T., Overall J. C., Jr, Glasgow L. A. A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice. Antiviral Res. 1981 Nov;1(4):225–235. doi: 10.1016/0166-3542(81)90013-9. [DOI] [PubMed] [Google Scholar]
  22. Kern E. R., Richards J. T., Overall J. C., Jr, Glasgow L. A. Acyclovir treatment of experimental genital herpes simplex virus infections. I. Topical therapy of type 2 and type 1 infections of mice. Antiviral Res. 1983 Nov;3(4):253–267. doi: 10.1016/0166-3542(83)90004-9. [DOI] [PubMed] [Google Scholar]
  23. Machida H., Ichikawa M., Kuninaka A., Saneyoshi M., Yoshino H. Effect of treatment with 1-beta-D-arabinofuranosylthymine of experimental encephalitis induced by herpes simplex virus in mice. Antimicrob Agents Chemother. 1980 Feb;17(2):109–114. doi: 10.1128/aac.17.2.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mayo D. R., Hsiung G. D. Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines. Antimicrob Agents Chemother. 1984 Sep;26(3):354–357. doi: 10.1128/aac.26.3.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mayo D. R., Lucia H. L., Hsiung G. D. Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs. Intervirology. 1983;19(1):26–32. doi: 10.1159/000149333. [DOI] [PubMed] [Google Scholar]
  26. Mindel A., Adler M. W., Sutherland S., Fiddian A. P. Intravenous acyclovir treatment for primary genital herpes. Lancet. 1982 Mar 27;1(8274):697–700. doi: 10.1016/s0140-6736(82)92618-6. [DOI] [PubMed] [Google Scholar]
  27. Nilsen A. E., Aasen T., Halsos A. M., Kinge B. R., Tjøtta E. A., Wikström K., Fiddian A. P. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982 Sep 11;2(8298):571–573. doi: 10.1016/s0140-6736(82)90658-4. [DOI] [PubMed] [Google Scholar]
  28. Pancic F., Steinberg B. A., Diana G. D., Carabateas P. M., Gorman W. G., Came P. E. Antiviral activity of Win 41258-3, a pyrazole compound, against herpes simplex virus in mouse genital infection and in guinea pig skin infection. Antimicrob Agents Chemother. 1981 Mar;19(3):470–476. doi: 10.1128/aac.19.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Reichman R. C., Badger G. J., Guinan M. E., Nahmias A. J., Keeney R. E., Davis L. G., Ashikaga T., Dolin R. Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis. 1983 Feb;147(2):336–340. doi: 10.1093/infdis/147.2.336. [DOI] [PubMed] [Google Scholar]
  30. Reichman R. C., Badger G. J., Mertz G. J., Corey L., Richman D. D., Connor J. D., Redfield D., Savoia M. C., Oxman M. N., Bryson Y. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA. 1984 Apr 27;251(16):2103–2107. [PubMed] [Google Scholar]
  31. Renis H. E. Chemotherapy of genital herpes simplex virus type 2 infections of female hamsters. Antimicrob Agents Chemother. 1977 Apr;11(4):701–707. doi: 10.1128/aac.11.4.701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schinazi R. F., Peters J., Sokol M. K., Nahmias A. J. Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrob Agents Chemother. 1983 Jul;24(1):95–103. doi: 10.1128/aac.24.1.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schinazi R. F., Scott R. T., Peters J., Rice V., Nahmias A. J. Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs. Antimicrob Agents Chemother. 1985 Oct;28(4):552–560. doi: 10.1128/aac.28.4.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sibrack C. D., Gutman L. T., Wilfert C. M., McLaren C., St Clair M. H., Keller P. M., Barry D. W. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis. 1982 Nov;146(5):673–682. doi: 10.1093/infdis/146.5.673. [DOI] [PubMed] [Google Scholar]
  35. Smee D. F., Martin J. C., Verheyden J. P., Matthews T. R. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983 May;23(5):676–682. doi: 10.1128/aac.23.5.676. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Straus S. E., Takiff H. E., Seidlin M., Bachrach S., Lininger L., DiGiovanna J. J., Western K. A., Smith H. A., Lehrman S. N., Creagh-Kirk T. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med. 1984 Jun 14;310(24):1545–1550. doi: 10.1056/NEJM198406143102401. [DOI] [PubMed] [Google Scholar]
  37. Wade J. C., McLaren C., Meyers J. D. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis. 1983 Dec;148(6):1077–1082. doi: 10.1093/infdis/148.6.1077. [DOI] [PubMed] [Google Scholar]
  38. de Clercq E., Montgomery J. A. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res. 1983 Mar;3(1):17–24. doi: 10.1016/0166-3542(83)90011-6. [DOI] [PubMed] [Google Scholar]
  39. de Clercq E. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. Antimicrob Agents Chemother. 1984 Aug;26(2):155–159. doi: 10.1128/aac.26.2.155. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES